You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto.
Results from the PROMPT registry presented at ASCO showed that 10 to 15 percent of women with variants in genes not linked to ovarian cancer had oophorectomies.
The prospective study will combine real-world, clinical, and genomic data to streamline lung cancer clinical trials and find treatment-response biomarkers.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
Research is accumulating for the improved performance of epigenetic signals over mutations, with multiple commercial efforts well underway.
At a real-world data workshop, Wendy Rubinstein said that labs have a responsibility under the 21st Century Cures Act to facilitate integration of genomic data into EHRs.
Presentations at this month's ASCO meeting demonstrated how efforts are advancing to determine when and how longitudinal ctDNA testing will be useful for oncologists.
Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
The mCODE team recently released standards for inputting genomic and other data into patient records to boost patient record transferability and trial participation.